Research programme: TAS2R modulators - Amaro Therapeutics
Alternative Names: Bitter taste receptor modulator - Amaro Therapeutics; TAS2R modulators - Amaro TherapeuticsLatest Information Update: 31 Mar 2023
At a glance
- Originator Amaro Therapeutics
- Class Antihyperglycaemics; Hepatoprotectants; Obesity therapies
- Mechanism of Action G protein-coupled receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Diabetes mellitus; Non-alcoholic steatohepatitis; Obesity; Polycystic ovary syndrome
Most Recent Events
- 16 Mar 2023 Early research in Diabetes mellitus in USA (unspecified route) (Amaro Therapeutics pipeline, March 2023)
- 16 Mar 2023 Early research in Non-alcoholic steatohepatitis in USA (unspecified route) (Amaro Therapeutics pipeline, March 2023)
- 16 Mar 2023 Early research in Obesity in USA (unspecified route) (Amaro Therapeutics pipeline, March 2023)